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Edited by Sandro SonninoAbstract Caveolin-1, the principal component of caveolae, is a
21–24 kDa integral membrane protein. The interaction of the
caveolin-1 scaﬀolding domain with signaling molecules can
functionally inhibit the activity of these signaling proteins. Little
is known about how caveolin-1 inﬂuences the expression of P-
glycoprotein (P-gp), an ABC transporter encoded by multi-drug
resistance (MDR1) gene. To elucidate the possible mechanism
between caveolin-1 and P-gp expression, in the present study, we
overexpressed caveolin-1 in the Hs578T/Dox breast adenocar-
cinoma cells, a multidrug resistant line, and then selected single
clone cells highly expressing caveolin-1 level. Both Western blot
and confocal microscopy analyses showed that caveolin-1 was
markedly overexpressed in the transfectants, while P-gp protein
was almost abolished. Reverse transcription polymerase chain
reaction also showed that the expression of P-gp mRNA was
signiﬁcantly suppressed in the transfectants. It was conﬁrmed
further by Northern blot analysis. Moreover, through measuring
the changes of drug resistance and P-gp transport activity in the
transfectants, we found that overexpression of caveolin-1
reversed drug resistance of transfectants and lowered their P-
gp transport activity to the level of Hs578T/S. Taken together,
our results indicate that such suppression of P-gp in the
transfectants overexpressing caveolin-1 may occur at the tran-
scriptional level.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Doxorubicin1. Introduction
Multi-drug resistance (MDR) is a major pitfall of chemo-
therapy in human cancer patients. MDR is often caused by
overexpression of P-glycoprotein (P-gp) encoded by the
MDR1 gene. P-gp, an ATP-binding cassette (ABC) trans-
porter, is responsible for MDR phenotype and is believed to
result in increased outward transport of active drugs and re-
duced the eﬀective concentration of them in the cytosol and
their cytotoxic eﬃcacy [1–4].* Corresponding author. Fax: +86-10-6487-0672.
E-mail address: chenmaci@sun5.ibp.ac.cn (J. Chen).
Abbreviations: Cav-1, caveolin-1; P-gp, P-glycoprotein; MDR, multi-
drug resistance; Rh-123, rhodamine-123; Dox, doxorubicin; DMSO,
dimethyl sulfoxide
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doi:10.1016/j.febslet.2004.09.041Caveolae are invaginations of the plasma membrane that are
enriched in cholesterol and sphingolipids. Caveolin-1, a 21-
kDa integral membrane protein, is a major caveolae coat
protein [5]. There is a growing body of evidence that a number
of proteins, such as H-ras, protein kinase Ca, G protein,
eNOS, src family tyrosine kinases and EGFR can directly in-
teract with a speciﬁc scaﬀolding domain of caveolin-1, which
consequently result in functional inhibitions of the activity of
these molecules, suggesting that caveolin-1 binding plays a
negative regulatory role in signal transduction [6–10]. Altering
caveolin-1 expression is thought to be involved in several im-
portant human diseases, including cancer, diabetes, Alzhei-
mer’s disease, cardiovascular disease and muscular dystrophy
[11–15].
Reports about the eﬀect of caveolins on the development of
MDR are controversial. On the one hand, caveolin-1 expres-
sion was upregulated in MDR phenotypes in a number of
human cell lines [4]. On the other hand, expression of caveolin-
1 and caveolin-2 was not detected in several MDR cell lines
that express high levels of P-gp [16,17], i.e., caveolin-1 ex-
pression is not associated with that of P-gp protein or MDR1
gene [18]. However, a physical interaction between caveolin-1
and P-gp in the caveolae membrane was observed in the
Hs578T cell and brain capillaries [19,20]. Caveolin-1 might
render the cells from drug-resistance to drug-sensitive by in-
hibiting the P-gp transport activity [19]. To further probe the
molecular mechanism on correlation between caveolin-1 and
P-gp, in the present study, we overexpressed caveolin-1 in the
Hs578T/Dox breast adenocarcinoma cells, a multidrug resis-
tant line, and then selected single clone cells highly expressing
caveolin-1 level. We examined the changes of P-gp and MDR1
gene in these single clones and compared the drug resistance
and P-gp transport activity in these cells. These results show
that the single clones overexpressing caveolin-1 decrease the
drug-resistance by suppression of the MDR1 gene expression.2. Materials and methods
2.1. Materials
Monoclonal antibody (mAb) against caveolin-1 was purchased from
Zymed Laboratories Inc. Anti-human P-gp mAb was obtained from
Signet Laboratories. FITC-labeled goat anti-mouse IgG and Texas
Red-labeled goat anti-mouse IgG were purchased from Molecular
Probe Inc. Cell culture supplies (RPMI 1640 medium, geneticin, fetal
bovine serum, L-glutamine, Trypsin-EDTA, LipofectAMIME 2000,
and Penicillin/streptomycin) and SuperScript One-Step reverse tran-
scription polymerase chain reaction (RT-PCR) with Platinum Taqblished by Elsevier B.V. All rights reserved.
Fig. 1. Caveolin-1, P-gp and PKCa expression in various Hs578T cells.
Western blot analysis of Hs578T/Dox+vector (lane 1), Hs578T/Dox
(lane 2) and Hs578T/Dox+cav-1 (lane 3). The detection was performed
with the BCIP/NBT reagents (A), and ECL with longer exposure for P-
gp (B). Representative electron micrographs (C), showing a large in-
crease in the number of caveolae organelles in cells overexpressing
caveolin-1 (bottom panel). Bar¼ 100 nm.
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reagents were purchased from Promega. DIG-11-dUTP, DIG Easy
Hyb Granules, DIG Wash and Block Buﬀer Set, Anti-Digoxigenin-
AP, Fab fragments and CDP-Star were obtained from Roche. Ve-
rapamil, cyclosporine A and rhodamine-123 (Rh-123) were purchased
from Sigma. The pCI-neo, pCI-neo-cav-1 plasmide and Hs5780T cell
lines were generous gifts of Dr. Eric J. Smart (Kentucky Medical
School, USA) [21] and Dr. Kjell Grankvist (Umea University, Sweden)
[22], respectively. All other reagents were obtained from regular
commercial sources with highest purity.
2.2. Cell lines, plasmids and transfections
The parental human breast cancer cell line Hs578T/S was cultured at
37 C, 5% CO2 in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 2 mM glutamine, 100 units/ml penicillin, and 100 lg/ml
streptomycin. Its doxorubicin (Dox)-resistant subclone Hs578T/Dox
was propagated in a culture medium containing 1 lg/ml Dox. The
entire cDNA sequence of caveolin-1 was cloned into the EcoRI site of
pCI-neo, to generate pCI-neo-cav-1. pCI-neo-cav-1 and its empty
vector were transfected into Hs578T cell lines as described [21]. After
ensuring the Cav-1 expression by Western blot, we counted cells, di-
luted them at 1 cell/200 ll and plated 100 ll per well in a 96-well plate.
Then, we picked up the well which contained only monoclonal pop-
ulation for propagation. Several Hs578T/Dox clones transfected with
either the vector alone or vector containing the Cav-1 cDNA wereestablished and analyzed for Cav-1 expression by Western blot. Three
clones, Hs578T/Dox (wild-type), Hs578T/Dox+vector and Hs578T/
Dox+cav-1 were chosen for further work.
2.3. Western blot
Proteins were separated by SDS–PAGE with a standard reducing
condition protocol and transferred to a nitrocellulose membrane.
Immunoblotting was performed with designated antibodies and de-
tection was performed with the BCIP/NBT reagents according to the
manufacturer’s instructions. Or horseradish peroxidase-conjugated
secondary antibodies (1:5000 dilutions, Pierce) were used to visualize
bound primary antibodies with the Supersignal chemiluminescence
substrate (ECL method).
2.4. Cell survival MTT assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide
colorimetric assay (MTT) was used to assess the sensitivity of the cells
to agents in vitro as described [23]. The survival percent was calculated
by the following equation: cell survival percent ¼ (mean OD of one
grade)/(mean OD of the blank control) 100%. The IC50 for Dox and
cisplatin were deﬁned as such a Dox and cisplatin concentration in
which the survival rate was 50%.
2.5. Eﬄux of rhodamine-123
To examine the transport activity of P-gp, eﬄux of Rh-123 was
measured [24,25]. Brieﬂy, the cells were harvested, then incubated with
2 lM of Rh-123 for 30 min at 37 C. After three times of washing to
remove the extracellular free dye, the cells were kept in dye-free media
or media containing 10 lM verapamil or 5 lM cyclosporine A at 37
C. The ﬂuorescence of remaining Rh-123 in the cells was monitored
by Becton–Dikinson FACS-420 ﬂow cytometer.
2.6. Confocal microscopy imaging
Confocal analysis was performed as described [7]. Immunostaining
was performed by incubation for 1 h in 1:200 diluted FITC-labeled
goat anti-mouse IgG or Texas Red-labeled goat anti-rabbit IgG. After
extensive PBS washes, immunostained cells were examined with a Bio-
Rad Radiant-2100 confocal microscope. More than 100 cells were
inspected per experiment and the results displayed are typical.
2.7. Reverse transcription-polymerase chain reaction
RNA from Hs578T cells was isolated with TRIzol Reagent. To
determine if MDR1 and caveolin-1 gene were expressed in Hs578T
cells, RT-PCR was performed using One-Step RT-PCR with Plati-
num by using speciﬁc human MDR1 primers [26] and caveolin-1
primers [27], respectively. 8 ll of each PCR product was electropho-
resed in 1 Tris/acetate/EDTA (TAE) electrophoresis buﬀer on a 1.2%
agarose gel, stained with ethidium bromide and detected by UV. To
ensure that RNA load was kept constant in all lanes, b-actin gene was
also ampliﬁed in the same condition, using following pair of primers:
50-GAT TAC TGC TCT GGC TCC TA-30 and 50-CAG TAA CAG
TCC GCC TAG AA-30.
2.8. Northern blot
10 lg of total RNA was separated on a 1% agarose/2.2 M formal-
dehyde gel and transferred to a Hybond-N membrane by vacuum
blotting. The nylon membrane was subjected to hybridization with a
digoxigenin (DIG)-labeled partial PCR products of b-actin, caveolin-1
and P-gp gene. Probe labeling, hybridization, washing and signal de-
tection were carried out according to manufacturer’s instructions.3. Results
3.1. Caveolin-1 and P-gp and PKCa content in Hs578T/Dox
Dox-resistant cells were transfected with pCI+neo-vector or
pCI+neo-caveolin-1. The single clone cells were selected and
proliferated. We have obtained three stable single clone cells:
Hs578T/Dox as wild-type, Hs578T/Dox+vector as vector
control cells, and Hs578T/Dox+cav-1 as transfectant cells
overexpressing caveolin-1 and parental cells Hs578T/S as drug
sensitive lines. Fig. 1 showed a result of detection by BCIP/
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transfectant cells were about 6-fold higher than wild-type and
vector control cells as detected by densitometry (Fig. 1A,
middle panels). Although P-gp was observed clearly in wild-
type and vector control cells, P-gp protein was almost abol-
ished in the transfectant cells (Fig. 1A, top panels). We used
higher sensitive ECL to detect P-gp in the transfectants.
Longer exposure was shown to better illustrate the P-gp band
(Fig. 1B). We also measured PKCa content in these cells, as a
positive control, and not found that a signiﬁcant change in
PKCa in the wild-type, vector control cells and in the trans-
fectant cells (Fig. 1A, bottom panels). We studied the impact
of overexpressing caveolin-1 on the caveolae organelles using
electron microscopy. As shown in Fig. 1C, the number of
caveolae increased greatly in transfectant cells. These caveolae
appeared as attached omega-shaped ﬂasks and bunches like
clusters of grapes.
3.2. Localization of caveolin-1 and P-gp in Hs578T/Dox
To identify the results as described above about the ex-
pression of caveolin-1 and P-gp in the transfectants, we applied
confocal microscopy to locate caveolin-1 and P-gp in which
various stable single clone cells were stained with FITC-labeled
goat anti-mouse IgG (Fig. 2A) or Taxes Red-labeled goat anti-
rabbit IgG (Fig. 2B) for 1 h. We observed localization of P-gp
(Fig. 2A, a, green color) and caveolin-1 (Fig. 2B, b, red color)
in vector control cells (Fig. 2, top panel). Both chromophores
superimposed in the same image, showing yellow color
(Fig. 2C, c). In contrast, the transfectants (middle panel) and
Hs578/S (bottom panel), a drug sensitive cells subjected to the
same confocal analysis did not show positive staining with
green color (Fig. 2A, d and g), although caveolin-1 with red
color could be observed in both of the cell lines (Fig. 2B, e and
h). The confocal result is consistent with that of Western blot.Fig. 2. Confocal analysis of P-gp and caveolin-1 localization in various
Hs578Tcells. Immunoﬂuorescence staining of Hs578T/Dox+vector
(top panels), Hs578T/Dox+cav-1 (middle panels) and Hs578T/S (bot-
tom panels) cells with anti-P-gp antibody (A, green color) and anti-
caveolin-1 antibody (B, red color) is shown. The both staining were
superimposed to indicate the colocalization of P-gp and caveolin-1 (C,
yellow color). Bar¼ 10 lm.3.3. Expression of caveolin-1 and P-gp mRNA in the
transfectants
In order to elucidate the expression mechanism of P-gp in
the transfectant cells, the mRNA of P-gp was determined by
means of RT-PCR. To ensure equal loading, the expression of
b-actin mRNA was used as control. As shown in Fig. 3A, P-gp
mRNA was not observed in the transfectants and in the drug
sensitive cells (Fig. 3A, lanes 7 and 8), although it was found in
wild-type and vector control cells (Fig. 3A, lanes 5 and 6).
However, the expression of caveolin-1 mRNA can be observed
clearly in the four cell lines (Fig. 3A, lanes 1–4). The sup-
pression of P-gp mRNA expression in caveolin-1 transfectant
cells was supported further by Northern blot analysis. As
shown in Fig. 3B, P-gp mRNA expression was only detected in
the wild-type and vector control, however, it was almost
abolished in the transfectants and drug sensitive cells (Fig. 3B,
top panel). Similarly, caveolin-1 can be detected in the four cell
lines (Fig. 3B, middle panel). The disappearance of P-gp
mRNA suggests that the endogenous transcription of P-gp
gene may be suppressed by transfected caveolin-1 gene.
3.4. Multidrug resistance in Hs578T/Dox
A line of evidence showed that many cases of MDR are due
to overexpression of P-gp. It is very likely that the drug re-
sistance is reduced once P-gp disappears in the transfectants.
To test this possibility, we selected a speciﬁc substrate of P-gp,
Dox, and a non-speciﬁc substrate, cisplatin, to study the
changes of drug resistance in the transfectants. As shown in
Fig. 4, the vector control (Fig. 4A) appeared to be much more
drug resistant, while caveolin-1 transfectants (Fig. 4B) couldFig. 3. Analysis of caveolin-1 mRNA andMDR1 mRNA expression in
various Hs578T cells. (A) RT-PCR, Hs578T/Dox cells (lanes 1 and 5),
Hs578T/Dox+vector cells (lanes 2 and 6), Hs578T/Dox+cav-1 cells
(lanes 3 and 7) and Hs578T/S cells (lanes 4 and 8). b-actin was used as
the internal control. (B) Northern blot, Hs578T/Dox+vector cells (lane
1), Hs578T/Dox cells (lane 2), Hs578T/Dox+cav-1 cells (lane 3) and
Hs578T/S cells (lane 4).
Fig. 4. Multi-drug resistance in various Hs578T cells. Dox was used to
study the changes of drug resistance in Hs578T/Dox+vector cells (A),
Hs578T/Dox+cav-1 (B) and Hs578T/S cells (C). The data are the mean
values (standard error) of three independent experiments.
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sensitive line cells (Fig. 4C). The IC50 values for Dox in the
transfectants and drug sensitive cells were about 1.3 and 0.3
lg/ml, respectively, while the IC50 in the vector controls was 95
lg/ml. This equates to a decrease in drug resistance in terms of
the IC50 values of 98% in the transfectants expressing caveolin-
1. The IC50 for cisplatin in the transfectants, drug sensitive
cells and the vector controls were 8.3, 6.9 and 19.8 lg/ml, re-
spectively. These data demonstrate that overexpression of
caveolin-1 cells markedly reduces the multidrug resistance in
Hs578T/Dox cells.
3.5. P-gp transport activity in Hs578T/Dox
The reduced drug resistance in the transfectants is likely
caused by the suppression of P-gp gene associated with cave-
olin-1 overexpression. We measured P-gp mediated transport
activity by decreasing the intracellular ﬂuorescence of Rh-123,
a P-gp substrate [25,28], via ﬂow cytometry. The higher the
ﬂuorescence intensity of remaining Rh-123 in the cells, the
lower P-gp transport activity. As shown in Fig. 5, the Rh-123Fig. 5. P-gp transport activity in various Hs578T/Dox. (A) The Rh-123 ﬂuore
Dox+cav-1 (Cav-1) and Hs578T/S (S), respectively. (B) Eﬀect of P-gp block
rescence intensity distribution in Hs578T/Dox+vector (Vector). (C) Eﬀect of
Hs578T/Dox+cav-1 (Cav-1).ﬂuorescence intensities were diﬀerent in the three cell lines:
Hs578/S> the caveolin-1 transfectantsHs578T/Dox+vec-
tor, i.e., 669 40, 279 25 and 37 10, respectively (Fig. 5A).
This result indicates that P-gp transport activity is lower in
caveolin-1 transfectant cells than in vector control cells, con-
sistent with the relative expression levels of P-gp. To conﬁrm
the speciﬁcity of the Rh-123 eﬄux from these cells, we em-
ployed two P-gp blockers, verapamil and cyclosporin A. Both
the inhibitors were able to signiﬁcantly enhance Rh-123 ac-
cumulation (decrease P-gp transport activity) in vector control
cells. The ﬂuorescence intensity increased 21- and 51-folds for
the cells by using 10 lM verapamil and 5 lM cyclosporine A,
respectively (Fig. 5B). However, the ﬂuorescence intensity in-
creased only about 4- and 5-folds for transfectant cells by using
same blocker concentration (Fig. 5C). The low sensitivity of P-
gp to blockers indicates that P-gp content in the transfectants
drastically decrease due to suppression of MDR1 gene by
overexpressing caveolin-1. The result is consistent with that of
Western blot, RT-PCR and Northern blot experiments.4. Discussion
The eﬀectiveness of chemotherapy to human tumors has
been largely limited by the development of drug resistance.
Numerous studies demonstrated that major mechanism un-
derlying drug resistance is overexpression of the MDR-1 gene
encoding for the transmembrane eﬄux pump, P-gp. For in-
stance, verapamil and carvedilol reversed cellular drug resis-
tance by inhibiting P-gp drug eﬄux in vitro as well as in vivo
[22,29]. These results have led to clinical trial of the agents in
refractory cancer patients.
Recent studies suggested that a role of P-gp in drug eﬄux is
regulated by protein phosphorylation/dephosphorylation. The
incubation of MDR cells with PKC activator and the trans-
fection of MCF-7 cells expressing MDR1 with PKCa, caused
P-gp phosphorylation, reduced drug accumulation, and en-
hanced drug resistance [30–32]. The expression of PKCa an-
tisense cDNA in same cells decreased P-gp phosphorylation
and its transport activity, and reversed drug resistance [33].
Caveolin-1, a major scaﬀolding protein in caveolae, is an-
other protein relevant to MDR and P-gp. Caveolin-1 is colo-scence intensity distribution in Hs578T/Dox+vector (Vector), Hs578T/
ers, cyclosporine A (CsA) and verapamil (Vera), on the Rh-123 ﬂuo-
both P-gp blockers on the Rh-123 ﬂuorescence intensity distribution in
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[19,20]. The interaction of caveolin-1 scaﬀolding domain with a
consensus caveolin-binding motif of signaling molecules can
functionally inhibit the activity of these molecules. This cave-
olin-bindingmotif is also present in human P-gp between amino
acid residues 36 and 44 [20]. It is noteworthy that most of the
investigations on relationship between caveolin-1 and P-gp/
MDR1measured either their mRNAor their protein expression
in cancer cells. Few of these studies simultaneously analyzed
functionality of caveolin-1 and P-gp. It may not be suﬃcient to
understand the biological signiﬁcance. For example, a high
MDR1 mRNA and P-gp expression was not accompanied by
low cellular drugs accumulation or sensitivity to eﬄux blockers,
in other words, P-gp expression may not be correlated with the
enhanced drug accumulation and cytotoxicity [34–36].
In order to gain insight into the possible mechanism between
caveolin-1 and P-gp expression, we have selected single clones
of high caveolin-1 expression levels from Hs578T/Dox over-
expressing caveolin-1 and employed multiple complementary
approaches to analysis the expression levels of both proteins
and mRNA of caveolin-1 and P-gp. At the same time, we
examined the changes of drug resistance and P-gp transport
activity in stable single-clone cells. It is believed that the de-
velopment of MDR in cancer cells is due to the increased ex-
pression of P-gp. We demonstrate in this study that the
expression of P-gp protein and mRNA is almost abolished in
the transfectants overexpressing caveolin-1 by using Western
blot, confocal microscopy, RT-PCR and Northern blot anal-
ysis. Moreover, the overexpression reverse cellular drug resis-
tance of the transfectants and decrease P-gp transport activity
to the level of Hs578T/S. A low sensitivity to P-gp blockers
also indicates that P-gp content in the transfectant cells dras-
tically decrease due to the suppression of MDR1 gene by
overexpressing caveolin-1. In order to make our results to be
convinced, we detected PKCa, which is localized in caveolae
too (6, 20), as a positive control. PKCa content was not sig-
niﬁcantly changed either in wild-type, vector control cells or in
the transfectant cells. It was possible, at least from our study,
that the suppression of P-gp mRNA by overexpressing cave-
olin-1 in Hs578T/Dox is speciﬁc. Although we do not know the
mechanism underlying P-gp suppression in transfectants, our
results imply that the suppression of P-gp in the transfectants
may occur at the level of transcriptional control. Analogously,
a recent study showed that the overexpression of regucalcin in
cloned rat hepatoma H4-11-E cells induced complete abol-
ishment of Ha-ras mRNA expression in the transfectants [37].
It was demonstrated that caveolin-1 expressed in most nor-
mal cells, but was downregulated in human cancer cells [38–40].
Working on embryonic ﬁbroblasts from knockout mice sup-
ports the idea that cell proliferation increases when caveolin-1 is
absent [41]. This indicates that the downregulation of caveolin-1
expression may be relevant to the development of human tu-
mors. Caveolin-1 gene in human is mapped to a common lo-
cation in chromosome 7q31.1, and is possible candidates for
tumor suppressor gene postulated in the region [42]. Caveolin-1,
as a ‘‘tumor suppressor’’, interacts with some signaling mole-
cules and inhibits their activity. Caveolin-1 had no sooner
downregulated than the cells began to proliferate highly (such
as, cancer cells) due to getting rid of this caveolin-1 inhibition on
signaling molecules. However, the role of caveolin-1 in multi-
drug resistance is still unclear. It is possible that caveolin-1 plays
a key role in signaling transduction in multiple mechanisms.The results from our and other study groups demonstrated that
a direct interaction between caveolin-1 and P-gp, and the
functional inhibition of P-gp transport activity were observed in
Hs578T/Dox and brain capillaries [19,20]. And a number of
evidences showed that the alterations of the physical state (for
example, ﬂuidization) and cholesterol content in the plasma
membrane of multidrug resistant cancer may indirectly eﬀect P-
gp transport activity and reverse MDR phenotype [43,44]. We
have also demonstrated that overexpression of caveolin-1 in
Hs578T/Dox cells could decrease the plasma membrane cho-
lesterol level, i.e., increase membrane ﬂuidity and indirectly
inhibit P-gp transport activity [45]. Other modulation mecha-
nism by the results presented here is that the overexpression of
caveolin-1 in single clone cells of Hs578T/Dox may suppress
MDR1 gene expression and reverse multidrug resistant.
In order to enhance the eﬃcacy of chemotherapy and de-
crease multidrug resistance in cancer therapies, we bring an
insight into overcoming drug resistance, in which caveolin-1
improve the eﬃcacy of cancer therapy by raising the accu-
mulation of chemotherapeutic drugs in cancer cells through
blocking the expression of MDR1 gene. The capability of
caveolin-1 in the reversal of multidrug resistant is consistent
with its role called ‘‘tumor suppressor’’. Further study eluci-
dating the detailed mechanism for caveolin-1 suppression of P-
gp expression should be performed.
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